SEC Filing Summary: Salarius Pharmaceuticals, Inc. (SLRX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. on April 29, 2020, covering events occurring on April 24, 2020. The filing discloses the execution of a new employment agreement with Mark J. Rosenblum, the Company's Chief Executive Officer and Executive Vice President of Finance. Note: The request metadata referenced "Decoy Therapeutics Inc.," but the source text explicitly identifies the registrant as Salarius Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to executive compensation terms.
Material Changes
The primary material change is the formalization of executive compensation terms for the CEO. The new agreement establishes a fixed annual base salary and a performance-based bonus structure, replacing or updating prior arrangements.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, market outlook, or management commentary regarding the Company's business strategy or future prospects. It focuses solely on the contractual terms of the CEO's employment.
Executive Compensation Details
- Base Salary: $265,000 annually.
- Target Bonus: 35% of base salary, contingent on performance objectives set by the Compensation Committee.
- Benefits: Eligibility for standard company-sponsored plans (medical, dental, life, disability) and perquisites.
- Termination for Cause/Death/Disability/Resignation: Entitlement to accrued salary, unused vacation, and benefits; no severance.
- Termination without Cause/Resignation for Good Reason: Severance equal to nine months of base salary paid in installments, plus nine months of COBRA reimbursement. Receipt of severance requires a formal release of claims.
Investor Verification Checklist
- Verify the exact definitions of "Cause" and "Good Reason" in the attached Exhibit 10.1 (Employment Agreement).
- Confirm the specific performance objectives required to earn the 35% target bonus.
- Review the Company's cash position to assess the impact of potential severance obligations (nine months of salary) on liquidity.
- Check for any prior employment agreements to understand the magnitude of the compensation change.